A multi-institutional team led by The University of Osaka developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team identified a monoclonal antibody called KG2032 that reacts with a certain variant of the HLA-DRB1 molecule. KG2032 CAR T cells displayed strong anti-AML effects in a mouse model, and CAR natural killer cells showed similar results. Clinical trials are currently being planned. 

A pan-Canadian team has developed a new way to quickly find personalized treatments for young cancer patients, by growing their tumours in chicken eggs and analyzing their proteins. The team, led by researchers from the University of British Columbia and BC Children’s Hospital Research Institute, is the first in Canada to combine these two techniques to identify and test a drug for a young patient's tumour in time to be used for their treatment. Their success in finding a new drug for the patient, described today in EMBO Molecular Medicine, shows how the study of proteins, known as proteomics, can be a valuable complement to the established study of genes (genomics) in real-time cancer therapies.

A Nature Medicine paper by City of Hope and Memorial Sloan Kettering (MSK) Cancer Center outlines a new tool that measures blood inflammation as a marker for poor CAR T therapy outcomes

A new form of tumor infiltrating lymphocyte (TIL) therapy, a form of personalized cancer immunotherapy, dramatically improved the treatment’s effectiveness in patients with metastatic gastrointestinal cancers, according to results of a clinical trial led by researchers at the National Institutes of Health (NIH). The findings, published April 1, 2025 in Nature Medicine, offer hope that this therapy could be used to treat a variety of solid tumors, which has so far eluded researchers developing cell-based therapies.

Researchers from Tel Aviv University have developed an innovative method that can help to understand better how cells behave in changing biological environments, such as those found within a cancerous tumor.

The cancer center at the University of Rochester is the 73rd National Cancer Institute-designated center in the U.S. 

Lung cancers with SMARCA4 deficiency are rare, typically showing aggressive behavior and poor prognosis. These tumors rarely harbor common targetable oncogenes like EGFR, ALK, or ROS1. This case report details a nonsmoking middle-aged woman with SMARCA4-deficient non-small cell lung cancer (NSCLC) and rare EGFR mutations who achieved significant tumor response with afatinib.